Phase II trial of efgartigimod
Latest Information Update: 04 Nov 2020
At a glance
- Drugs Efgartigimod alfa (Primary)
- Indications Unspecified
- Focus Therapeutic Use
- Sponsors argenx
- 04 Nov 2020 New trial record
- 22 Oct 2020 According to Argenx media release, indication details, including on biology rationale, trial design and commercial opportunity, to be shared during investor event in first half of 2021
- 22 Oct 2020 According to Argenx media release, preparations are underway to initiate this trial in fifth rare disease indication by mid-2021